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Big data are no longer an obstacle; now, by using artificial intelligence (AI), previously undiscovered
knowledge can be found in massive data collections. The radiation oncology clinic daily produces a large
amount of multisource data and metadata during its routine clinical and research activities. These data
involve multiple stakeholders and users. Because of a lack of interoperability, most of these data remain
unused, and powerful insights that could improve patient care are lost. Changing the paradigm by intro-
ducing powerful AI analytics and a common vision for empowering big data in radiation oncology is
imperative. However, this can only be achieved by creating a clinical data science community in radiation
oncology. In this work, we present why such a community is needed to translate multisource data into
clinical decision aids.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 153 (2020) 43–54 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).The clinic as a learning health care system
Many large commercial enterprises are redirecting their busi-
ness approaches to exploit the new knowledge they can gain from
the data they collect daily. This strategy arose from the need tomine a large amount of diverse data, often unstructured and com-
ing from multiple sources: so-called ‘‘big data.” Whereas initially
big data seemed to present an obstacle, now it is becoming more
evident that leveraging massive data collections using novel tech-
niques can reveal previously undiscovered knowledge [1,2]. These
techniques include analytic methods spanning from traditional
statistics and hypothesis testing to more advanced algorithms
inspired by machine learning (ML), a branch of artificial intelli-
gence (AI), in which powerful computational systems augment
our brain’s learning capacity by employing complex mathematical
algorithms to reveal patterns in data, mainly for the purpose of
generating new knowledge [3,4]. AI is not a new concept in oncol-
ogy. Recent reviews described two major applications of AI in the
medical field: automation and decisions’ augmentation [5,6]. The
former includes applications such as auto contouring of both
organs at risk (OAR)s and target volumes; the latter covers the
whole spectrum of decision support systems. However, by compar-
ing applications in the enterprise domain, AI is often referred to as
‘‘data analytics”. In this view, two powerful applications of AI in
medicine are often forgotten, namely the ability of AI to retrieve
The need for a clinical data science community in oncologydata belonging to multiple sources and spread across different
locations. Most of the big-companies’ data analytics include pow-
erful tool that can collect data from multiple sources, such as for
example social media or health wearables. This part of AI is very
useful, because of the intrinsic nature of multisource data: they
are sparse and unstructured. The second powerful aspect of AI is
that, after having retrieved multisource data, automated QA can
be performed. This aspect of AI is often forgotten, but in radiation
oncology data quality is fundamental for applying AI in the clinic.
After automated QA, which starts from unstructured data (often
referred to as ‘‘veracity” of big data), data are transformed into a
network of knowledge, the so-called ‘‘linked-data”, resulting in
new knowledge. We believe this broader view of AI is key to a
new era in our healthcare systems.
Translating this new learning paradigm into radiation oncology
will improve the classification of disease and reveal new ways to
improve cancer treatment and predict patients’ clinical events.
Unfortunately, the radiation oncology community lags far behind
in the adoption of big data approaches for providing the patient-
centered, individualized care often referred to as personalized
medicine [7]. With the term radiation oncology community, we
do not only refer to radiation oncologists, but the extensive com-
munity concerned with treating cancer patients with radiotherapy.
The treatment is rarely only consisting of radiotherapy but is often
multimodal and consisting of radiotherapy in combination with
chemotherapy, immunotherapy and/or surgery involving multiple
professionals such as radiologists, pathologists, surgeons, medical
physicists, and medical- and radiation oncologists.
While the community agrees that the future of medicine as a
whole and radiation oncology in particular is in learning health
care systems, where data are transformed into new knowledge as
part of clinical routine, there remain gaps in our ability to rapidly
learn from data generated in the clinic during the course of patient
care [5]. By definition a learning health care system is a system that
has been designed to generate and apply the best evidence gener-
ated from a collaborative effort among patients and care
providers.” The central point of a learning healthcare system is that
knowledge discovery becomes a natural outgrowth of patient care.
A learning healthcare system is meant to push forward evidence-
based medicine by: a) fast translation from knowledge produced
in clinical research to clinical practice; (b) empowerment of a
shared responsibility culture between the different stakeholders
involved in the clinic; and (c) facilitating engagement of patients
and doctors for evidence production and dissemination [8].
In radiation oncology, we still mainly learn by narrowing and
simplifying our research questions, in the process often moving
them far from the complexity of real-world clinical practice. For
example, most support for clinical decisions comes from clinical
trial data. On one hand, clinical trials can provide high-quality data,
but on the other hand, they have several major drawbacks: a) their
exclusion of patients with complex cases that do not fit their strict
inclusion criteria; b) their narrow focus on just one research ques-
tion or a limited number of questions that often determine the
choice of collecting specific variables; c) their high cost; d) the long
time required to recruit sufficient patients to reach statistically sig-
nificant results; and e) their infrequent exploration of how combi-
nations of several factors might influence patients’ outcomes.
Conversely, patients produce a vast amount of data, from diagnosis
to treatment and follow-ups. Only a small percentage of this data is
actively used to produce new insights that can push our clinical
practice and lessons learnt from clinical trials towards personal-
ized medicine. In this view, big data empowered with AI is not a
strategy to substitute randomized clinical trials, but rather a strat-
egy to augment the knowledge from clinical trials. For example, AI
can be used to explore multisource big data to better stratify
patients and optimize clinical trials enrollment by defining group44of patients for which the introduction of a new treatment is more
likely to be found beneficial. Finally, by leveraging multisource big
data a large spectrum of prognostic as well as confounding factors
can be examined. This data integrates and considerably expand the
original collections from randomized clinical trials. A recent com-
munitarian effort is being carrying on boosting the efficacy of RCTs.
This effort foresees the possibility to increase the ‘‘pragmaticism”
of RCTs. A detailed review [78] pointed out the prominent role of
AI in supporting this translation. By combining the expertise
brought by clinical data scientists and medical doctors it is possible
to use robust, validated and well understood AI tools to improve
trial success rates starting from trial design and preparation (e.g.
a better recruitment strategy) to execution.” A recent investigation
providing updating guidelines for more ‘‘pragmatic” RCTs, the
SPIRIT-AI [79], is supporting the above-mentioned transition and
it is currently adopted in recent clinical trial protocols that
included AI-driven intervention. These guidelines were needed
considering the increasing number of RCTs making use of AI tools.
It is important to highlight how specific attention and dedicated
methodologies need to be adopted when performing casual infer-
encing from both randomized clinical trials and multisource data
[9]. The same issues that exist for casual inferencing from observa-
tional studies, such as the presence of confounding factors, sam-
pling selection and cross-population biases also exist for
inferencing from aggregated data (e.g. multisource data). A recent
study [10] recommended the extension of parametric causal infer-
encing mathematical models specifically developed for clinical tri-
als to non-parametric models specifically developed for aggregated
data. The authors claimed that this methodology cannot be sepa-
rated from the AI analytical tools used to process that data. This
is indeed a key point, which need to be combined with the need
of improving data quality (see coming statements) for robust
casual inferencing.
The fuel of a learning health care system in radiation oncology
is the data that are generated every day in the clinic. This requires
us to reimagine the clinic as a source of big data. Currently, most of
the big data generated in the clinic are wasted as a source of
research because we have been unable to equip the clinic with
big analytics. Nevertheless, we cannot support a learning paradigm
in radiation oncology solely by borrowing technologies from other
fields, such as business enterprises. The path towards a learning
health care system in radiation oncology needs to pass several
milestones, which are summarized in Fig. 1. All these milestones
represent shifts in our concept of traditional clinical medicine.
These milestones are:
 M1: Understanding the clinic as a source of big data: Where do
the data come from and why are the data ‘‘big?” Data are not
only produced directly by daily routine clinical activities, but
also indirectly, for example when researchers process clinical
data. This produces a combination of data and metadata, which
are logically connected but might be sparse, even within the
same institution. Combining and reunifying these data is the
largest challenge to be tackled.
 M2: Identifying data types and involved stakeholders. The gen-
eration of multisource big data involves different professions
and users. It is fundamental to identify not only the users and
stakeholders of these data but also the major constraints that
limit the interoperability of these data. Interoperability and
data housekeeping are the keys for boosting data quality.
High-quality data will have a strong impact on the robustness
and integrity of our data-driven clinical decisions.
 M3: Defining which data analytics can be used to extract unique
insights from multisource data. After we learn how to correctly
retrieve, curate, mine, and combine multisource big data, it is
Fig. 1. Overview of the milestones for moving the clinic towards a learning health care system. Five milestones have been identified. Milestones 1 and 2 involve developing a
deep understanding of clinical data as a source of big data and metadata and the need to involve stakeholders and users and to address issues that limit data interoperability.
M3 introduces robust and collaborative AI-driven analytics for the development of clinical decision aids. M4 introduces a new clinical data science community for radiation
oncology to harmonize existing initiatives and define a code of conduct. M5 introduces a patient-centered view and decision-making processes for the learning health care
system.
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use of AI per se does not guarantee success. Strong transparency
and robust methodology will enable meaningful applications of
AI to discover new knowledge in the data. This methodology
should comprise both analytics for verifying data quality, as
well as methods for tackling the issues related to causal infer-
encing from aggregated data.
 M4: Defining working statements and a code of conduct to
rapidly translate data analytics into the clinic as decision aids.
To fill the gap between AI developments and their translation
into the clinic as decision aids, a global effort to involve all
the professional figures, stakeholders, and users identified at
M2 is needed. This effort requires the creation of a clinical data
science community in radiation oncology. Such a community
would not replace previous efforts or already-existing focused
work and task groups, but instead act as a harmonizer by
defining a code of conduct and a shared vision.
 M5: A patient-centered learning health care system. The
brand-new learning health care system has to be made
patient-centered by a) developing AI analytics to include
patient perspective data; b) improving the expandability of AI
analytics, and c) using decision aids in combination with shared
decision making.
Multisource data, data types, and stakeholders (M1 and M2)
The clinic is a source of big data. Common data types include
medical images, electronic health records (EHRs), and patient-
reportedoutcomes [11].However, the clinic also indirectlyproduces
metadata associatedwith traditional data types from the algorithms
that process data [7]. Examples are quantitative imagingbiomarkers
and radiomic data (large amounts of features extracted frommedi-
cal images and analyzed using data characterization algorithms),
which generate predictive or prognostic factors from source data.
In Table 1, we summarize the main types of these highly variable
multisource data and provide descriptions of the commonly avail-
able formats, the data owners, stakeholders, and users, and issues
with or barriers to interoperability of the data.45AI to empower multisource data (M3)
One of the largest issues faced when dealing with multisource
big data is that the ability to process these data is beyond our
human brain capacity. However, recent developments in AI algo-
rithms have emerged as attractive and much-needed tools to
empower multisource data analysis. AI and ML have created
opportunities to build powerful computational facilities and a
surge in data sharing, data collection, and advanced data mining
algorithms. The use of ML algorithms in radiation oncology is
rapidly growing; their main applications are quality assurance,
organ segmentation, treatment planning, image guidance, motion
tracking, and treatment response modeling. However, radiation
oncology has not yet fully exploited the enormous potential of AI
for analyzing multisource data that integrate variables from
time-dependent sources, such as sequential quantitative imaging
or genetic biomarkers. These developments could change the clas-
sical paradigms for radiotherapy by automating and optimizing
clinical processes and quality control to provide decision support
for personalized patient care, for instance by altering radiotherapy
prescriptions and fractionation schedules. Hence, AI-based analysis
of multisource data could dramatically change the way radiother-
apy is approached and will likely play a central role in the future
development of personalized, precision medicine.
Despite the great potential of AI, the current situation in radia-
tion oncology is that only a small percentage of the data collected
is used for decision-making in the clinic owing to several obstacles
that hinder the sharing, processing, and deployment of data in the
clinic. By throwing these data in the ‘‘trash,” we risk losing unique
insights that could radically change our clinical practice. We need
to realize that human capabilities are not sufficient to process big
clinical data and that clinicians need the help of AI to fully translate
the large amounts of data collected in the clinic into decision-
making about routine clinical practice. Artificial intelligence in
clinical care is recently being recognized as a medical device by
the FDA, with applications spanning from medical imaging analy-
sis, clinical decision aids and tools to optimize patient care
[80,81]. These applications not only apply to the USA, but similar
evidence is seen in Europe and Asia. The FDA has developed a
Table 1
Summary of the main data types available for multisource data analysis.
Data type Description and Common format Stakeholders Data users Major issues for Interoperability
EHRs EHRs are computerized medical information systems that collect,
store, and display patient information.
Patients
Hospitals
Clinicians
Nurses
Medical physicists
Researchers
Radiation therapists (RT/
RTT) and dosimetrists
Administrative staff
Free-text entries
Outcome
measures
Data on survival, recurrence, and toxicities are commonly found in
the EHR, but when part of clinical trials, data can also be found in
spreadsheets or electronic/paper-based case report forms.
Patients
Hospitals
Clinical trial
units
Study
funders
Regulatory
agencies
Clinicians
Researchers
Research nurses
Clinical data coordinators
Lack of standardization Free-text
entries Consistency and
completeness of collected data
Laboratory data Software and databases used to manage and store results from
laboratory tests and pathology data
Patients
Hospitals
Clinicians
Nurses
Engineers
Researchers
Lack of standardization
in acquisition and analysis
Non digital format
Image storage, management,
transmission and sharing
Genomics Separate databases for large-scale genomic data Patients
Hospitals
Clinicians
Researchers
Medical images Medical images are acquired for diagnosis, staging, and treatment
planning. The most common modalities include PET, CT, CBCT,
MRI, and ultrasonography. Medical images are regulated by a
commonly accepted standard (DICOM).
Patients
Hospitals
Clinicians
Medical physicists
Radiation therapists
Researchers
Lack of standardization in
acquisition and analysis
Duplication of data within same
Institution
Radiotherapy
TPS &
Verification
Systems
Dose-volume histograms, metrics for radiation dose delivered to
the tumors and organs at risk at single treatments and over the
whole treatment course, are saved in the TPS.
Plan information
Dose distribution Treatment delivery data
Patients
Hospitals
Clinicians
Medical physicists
Radiation therapists
Institutional and clinician bias in
treatment
Data accessibility and full use of
data for data analytics
Patient-
reported
outcomes
Patient-reported outcomes, such as treatment-induced side
effects, can be found in the EHR if part of standard treatment. For
clinical trials, there may be various types of electronic or paper
forms.
Patients
Hospitals
Clinicians
Nurses
Researchers
Lack of standardization
Free-text entries Consistency and
completeness of collected data
National cancer
registries
Population-based registries of cancer incidence, treatment, and
outcomes are often recorded in national databases.
Health
authorities
Clinicians
Researchers
Government
Institutional bias diagnosis,
treatment, and follow-up.
Free-text entries.
Nonmedical
information
Environment, income, socioeconomic status, race, ethnicity,
education, housing
Local
government
Government
Researchers
Information bias
Abbreviations: EHR, electronic health record; PET, positron emission tomography; CT, computed tomography; CBCT, cone beam computed tomography; MRI, magnetic
resonance imaging; TPS, treatment planning system.
The need for a clinical data science community in oncologycomplete product lifecycle for AI applications, like what was con-
ceived for medical devices [82]. A nice example of combining big
data with AI is presented in the study by Mayo et al, where a deci-
sion support system is used to improve dose delivery to spare
health tissues [83].A patient-centered clinical data science community in radiation
oncology (M4 and M5)
The key to success at achieving the above-mentioned mile-
stones is the creation of a new community: one focused on clinical
data science in radiation oncology. Because multiple stakeholders
are involved, the problems of big data cannot be solved by only
one professional discipline; instead, they will require a joint effort
bringing together broad, multidisciplinary expertise and including
clinicians, medical physicists, data scientists, biologists, patients,
and other stakeholders. However, instead of proposing an indepen-
dent community, we recommend building upon already-existing
working groups and task groups that touch these professional
roles. To coordinate these communities and working groups and
to speed the realization of a learning health care system, we pro-
pose the development of a collection of statements and a code of
conduct. Finally, we underline the importance of introducing tools
that enable not only the collection and elaboration of data report-
ing patients’ perspectives, but also a synergy between clinicians,
decision aids, and patients.46Vision and statements
With this position paper, we offer a basis for shifting the current
paradigm in radiation oncology towards the clinic as a learning
health care system. In the subsequent sections of the paper, we will
elaborate on five supporting statements that are fundamental to
reach the above milestones. For each statement, we have identified
already-existing activities, efforts, or smaller communities that
will be our main interlocutors in coordinating these efforts within
the community. An overview of the statements is provided in
Fig. 2.Statement 1: FAIR principles for data management plans
Over the past ten decades, numerous patient registries and
databases have been established worldwide. However, few people
know of their existence, let alone how to access the information in
them. This lack of exposure and accessibility limits the power and,
hence, the potential benefits of ML/AI tools, since a model’s perfor-
mance directly correlated with the amount of information it learns
(trains) on, as seen in Statement 4. The need to improve the infras-
tructures that support the use and reuse of all these pieces of infor-
mation (multisource data) in their respective silos is therefore
paramount. To lay the groundwork for accomplishing this, a
diverse group of stakeholders—both private and academic—jointly
designed a set of principles referred to as the FAIR data principles
[12]. The FAIR principles urge that all data sets should be FAIR:
Fig. 2. Overview of the vision of the community, the milestones and the code of conduct statements.
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data privacy and patient confidentiality principles. The goal is to
improve data (re)use by providing detailed metadata descriptions
that are readable to both humans and machines, thereby making
data findable, accessible, and interoperable. Therefore, for multi-
source data to work as intended, all data sources must adhere to
the FAIR Guiding Principles and respect data privacy and
confidentiality.
With the dawn of this new, data-centric era, data can be
regarded as the new oil. Like crude oil, which differs in its physical
and chemical characteristics from region to region, data also differs
from one source or format to another. Because multisource data
stem from various sources and are collected using various meth-
ods, information can be incomplete, inconsistent, biased, or impre-
cise. Therefore, in using multisource data, answers to the following
five W-questions will facilitate the transparency of the data-
generation procedure:
o Who generated the data?
o Why were the data generated?
o When were the data generated?
o Where were the data generated?
o What generated the data?
The phrase ‘‘you are what you eat” applies not only to humans
but to models as well. The data science implication of this axiom
means that when a model feeds (trains) on ‘‘bad” data, the result-
ing model is inevitably bad—in other words, less accurate—and the
converse is almost always true. Therefore, no matter how compli-
cated a model might be, it will never catch extra information in the47data more effectively than a simple, explainable model would.
Ensuring the integrity and quality of multisource data is even more
essential if inferencing is envisaged.
In a multisource AI-driven radiotherapy system, clear guideli-
nes need to be laid out for data stewardship. The health care orga-
nization should incorporate metadata containing data provenance
at the source, and proper data lineages should be maintained at all
stages of data management. Adopting health care standards that
address data stewardship at the source and enable an audit trail
from data acquisition to data curation will ensure better traceabil-
ity for AI models.
Finally, data must be interoperable. Data from one source
should be semantically as well as syntactically interpretable across
different systems. Health care data structure and exchange stan-
dards like HL7 FHIR, OHDSI OMOP, and XDS provide the means
to structure data in globally acknowledged and accepted formats.
Use of clinical coding terminology systems and vocabulary (WHO
ICD, ICF, SNOMED CT, LOINC, etc.) should be encouraged. The focus
of adopting these standards should be to make the implementa-
tions of shared terminologies and vocabularies as generic as possi-
ble while permitting specificity as needed. In all cases, including
those in which adoption of a health care data exchange standard
is not possible, data should be sufficiently supported by metadata.Data quality and effects on AI applications
Data quality assurance is an essential exercise at all stages of
data curation, although the definition of ‘‘quality” is context
dependent and adopting a single measure to gauge quality is
challenging. The elements of data quality are accuracy, complete-
The need for a clinical data science community in oncologyness, consistency, credibility, and timeliness. By accuracy, we
mean that the intended value of the data is both correct and
unambiguous. A very preliminary way of ensuring accuracy at
the source is by using validation rules at the time of data acqui-
sition. However, as data are shared across domains, a validation
rule can itself become inconsistent, thereby increasing the
chance of the data’s being inaccurate. Jack Olson, in his book
Data Quality: The Accuracy Dimension, argues that data can never
be 100% accurate [13]. This is because the content of data can be
validated against permissible values but not against the actual
occurrence. He gives the example of how the value ‘‘brown”
for eye color can be a valid entry but not an accurate one, simply
because the person’s eye color may actually be blue. Thus, inac-
curacy can create bias in AI systems that may affect clinical out-
comes. However, the very AI systems that demand quality data
for better decision support may in fact contribute to improving
the quality of data at the source. While AI is largely seen as a
tool to extract value from data, it can also act as an instrument
to add value back to the data.Statement 2: Standardization of methodologies
Standardization of radiomic algorithms
The lack of standardization in image processing methods and
quantitative radiomic feature extraction, as well as the lack of val-
idated and verifiable reference values, is hampering the clinical
implementation of quantitative radiomic imaging biomarkers
[14,15]. A lack of standardized, consistent, clear, and sufficient
detail in reporting radiomic features, in addition to intrinsic issues
with repeatability and reproducibility [16], make radiomic findings
difficult to reproduce [17] and trust. Standardization of radiomic
algorithms and image processing pipelines is essential for the
development of the field and should be strongly encouraged. The
approach proposed by the Image Biomarker Standardization Initia-
tive [18], which includes the standardization of a set of 174 radio-
mic features, the definition of a general radiomics image
processing scheme, and the publication of imaging data sets and
reference feature values (https://theibsi.github.io), is the most
advanced effort to date. It is expected to continue and to be widely
accepted and used in the future [19].Standardization of image acquisition and phantoms
To be useful, quantitative imaging biomarkers must be both
repeatable and reproducible [20]. Radiomic features are affected
by acquisition, reconstruction, and image preprocessing settings
[21–25]. This applies to all imaging modalities. Standardization
and harmonization of imaging procedures are essential require-
ments for the development of robust, repeatable, and valid imag-
ing biomarkers. The standardization of imaging protocols for all
imaging modalities (computed tomography [CT], magnetic reso-
nance imaging, magnetic resonance spectroscopy, single-photon
emission CT, and positron emission tomography) should be
strongly encouraged within the same institution and across dif-
ferent institutions, as it would facilitate the interoperability of
quantitative imaging biomarkers [26,27]. This would be particu-
larly important when assessing treatment or tumor response on
a large scale and as part of clinical trials [28]. The standardiza-
tion of imaging protocols should be accompanied by the devel-
opment of new phantoms specifically designed to address the
challenge of providing reproducible reference values for textural
features [22].48Standardization of nomenclature within the radiation oncology
community
The adoption of a standard radiation oncology nomenclature
would enable and facilitate extraction and sharing of all types of
data from EHRs across different institutions, states, provinces,
countries, and continents. Such a standardized nomenclature
would support large international clinical trials, ease collabora-
tions across borders, and contribute to improvements in clinical
practice and patient care [29]. Moving forward, it is essential that
new clinical trial protocols use standardized nomenclatures for
capturing their data. The question remains which standard nomen-
clature should be used. At present, the standardized nomenclature
for radiotherapy proposed by the American Association of Physi-
cists in Medicine (AAPM) Task Group (TG) 263 [30] seems to be
the most likely standard to become accepted and widely used.
The Global Quality Assurance of Radiation Therapy Clinical Trials
Harmonization Group (https://rtqaharmonization.org) has recently
unified the contouring of organs at risk by compiling, in line with
AAPM TG 263 and the American Society for Radiation Oncology
(ASTRO), guidance for delineation and a standard nomenclature
for integration into clinical trial protocols [29].Statement 3: Privacy-preserving collaborative big data infrastructures
FAIR data principles ensure that data are syntactically and
semantically interoperable, thereby promoting seamless data shar-
ing among health care providers. While sharing patient-level data
for better decision making is important, protecting patient privacy
is essential. Ethical, legal, and societal issues regarding data shar-
ing bar hospitals and clinics from sharing data. When there is too
little data shared, ML and AI technologies starve themselves with
little or no data.
However, if we cannot bring data to the algorithms, it is possi-
ble to send algorithms to the data. Infrastructures built around
these data silos can connect and provide a way to send algorithms
to the data sources. While the data stays well protected within the
jurisdiction of the healthcare provider or the patient themselves,
the algorithms via the infrastructure can fetch results. This way
privacy of patient data is protected while at the same time,
research is promoted. This section explores big data infrastructures
that enables privacy preserving collaborative research.
We talk about two types of infrastructure: centralized collabo-
rative big data infrastructures and federated big data infrastruc-
tures. In centralized infrastructures, different hospitals and
healthcare providers enter a collaboration and upload patient data
to a secured centralized repository [31]. Researchers can use data
from the repository either train their algorithms and perform anal-
ysis. Additionally, the centralized repository can also provide a
compute environment where algorithms can be sent and computa-
tion performed. A researcher initiating a data analysis process will
have no direct access to the data and can only retrieve the result of
the analysis. However, it is important to mention that the data will
still be located outside individual hospitals. As such, patient’s con-
sent in sharing data to a central repository and use for secondary
purposes needs to be addressed properly. Another initiative, Infor-
matics for Integrating Biology and the Bedside (I2B2), aims to inte-
grate data from different biomedical disciplines and to deliver
these data to researchers. I2B2 provides tools and frameworks for
merging and linking genomic and biological data to clinical data
in a health data warehouse [32,33]. Similarly, the HMO Cancer
Research Network connects more than 11 million patient records
from 14 health care providers in a virtual data warehouse [34].
Federated big data infrastructure emphasizes keeping the data
at the source while pushing the analytics to the source. Each hos-
pital maintains a local data repository to which researchers can
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collaborative environment, each hospital would act as an individ-
ual data provider, generating sets of results that can then be aggre-
gated to obtain global results. An example is the Personal Health
Train (PHT) [35]. PHT shifts the focus from sharing data to sharing
algorithms to the source of the data, essentially within the jurisdic-
tional environment of the hospital. A researcher using the infras-
tructure is agnostic about the data schema and distribution at
the source and as such relies heavily upon the FAIR data principles.
Each hospital hosts a data station containing FAIR data, and pro-
vides a computation environment for the train (metaphor for pack-
age containing algorithms and data retrieval query). PHT is
platform independent and the researcher can autonomously
choose the technology for implementing the algorithm (e.g.,
Python, R, Matlab, Java). The communication between the data sta-
tions and researchers occurs through a secured and centralized
message broker. Study showed that PHT is scalable so that feder-
ated, privacy-preserving analyses involving many thousands of
patients can be conducted [36–39].
Another example is DataSHIELD, a collaborative and privacy-
preserving data analysis environment connecting multiple hospi-
tals. This infrastructure enables researchers to send algorithms to
the data without having to retrieve data locally. Unlike PHT, Data-
SHIELD sends algorithms packaged in the R statistical program-
ming environment to an Opal database hosted at each hospital
[40,41]. PCORnet is a network of several clinical research institutes
that supports pragmatic trials and comparative effectiveness
research across one or several of the participating institutes [42].
More recently, MedCO provided a privacy preserving federated
data analysis platform [43,44]. MedCO focusses on keeping data
at the source and provides multi-party homomorphic encryption
to all data sources, providing an additional layer of security and
privacy. OpenSAFELY initiative in the UK enables trusted analysts
to run large scale computation on pseudonymised patient records
inside environments managed by electronics health records soft-
ware company [45].
It is important to mention that creating a collaborative environ-
ment connecting many different hospitals and clinics while pre-
serving patient data privacy is a multifaceted challenge. Keeping
data at the source may not be sufficient when the amount of data
is small. The infrastructure needs to be adaptive, flexible, scalable,
and secure. It should be transparent to the patient and to society in
general to maintain trust. A balance between respecting privacy
and creating maximal societal benefits needs to be ensured. While
the data need to be FAIR, the analysis should be fair, accurate, con-
fidential, and transparent (FACT).
Finally, it is important to acknowledge the important role that
legal and professional bodies have in ensuring that there are
appropriate legislative frameworks in place that public and com-
mercial stakeholders can adopt and follow. At the heart of any cen-
tralized or federated multi-source data science initiative in
radiation oncology must therefore be full engagement with regio-
nal data protection regulations such as those set out in the Euro-
pean Union General Data Protection Regulations (GDPR), which
are now the cornerstone of data sharing initiatives in Europe.Statement 4: Involvement of clinicians in the data science
community
The clinician is an essential member of the data science community
For decades, decisions in medicine have been based on clinical
guidelines that are carefully developed and based on the highest-
level evidence from large randomized controlled trials. Recently,
individualized approaches to treatment have become an increas-
ingly compelling research area. This trend is particularly promi-49nent in oncology, where the discovery of new prognostic and
predictive factors including viral infection, hypoxia signatures, dri-
ver mutations, and many others has enabled more precise treat-
ment selection to match the characteristics of each patient and
tumor [46]. However, greater personalization makes generating
level-1 evidence difficult, if not impossible, as the number of
matched patients in each subgroup decreases, ultimately coming
down to a single individual.
Predictive modelling using AI and multisource data offers a way
to address this conundrum. The multidisciplinary field of clinical
ML attracts researchers from diverse disciplines, including clini-
cians, computer scientists, medical physicists, and biostatisticians.
Unfortunately, these different research communities often work in
isolation, with separate jargon, specialized publications, and her-
metic knowledge. Often, groups of scientists access partial data
but lack the full clinical context or a complete understanding of
the limitations of the data (e.g., embedded treatment effects)
because their expertise may not lie in the clinical domain. Thus,
to overcome these obstacles to the clinical implementation of AI
tools, close cooperation among specialties is mandatory.
The role of clinician is—and will remain—crucial to the clear
definition of a relevant clinical problem and the identification of
appropriate prediction targets, e.g. biologically relevant mecha-
nisms (hypoxia, gene expression) or cancer- and treatment-
specific outcomes like survival, relapse, and treatment toxicity.
Clinicians must be involved in both baseline data review and
model generation to detect garbage-in garbage-out situations aris-
ing from malformed or poorly designed models. Data science
approaches often highlight previously known clinical factors that
are already used clinically to select patients for treatment, which
can confound the interpretation of outcomes data. AI models that
detect and latch onto novel details of individual patient cases are
required so that these approaches can supplement, rather than
reiterate, current clinical practice.
Finally, and perhaps most importantly, clinicians will be the end
users of any deployed multisource-based ML tool; they will be the
ones to interpret the output of such tools to make responsible deci-
sions about patient care and provide feedback to improve the data-
base. Most clinicians trust their own experience and intuitions
developed over years of practice and might find it difficult to rely
on a model’s prediction, especially if they do not understand the
reasoning behind it. Thus, close collaboration between algorithm
developers and clinicians is necessary to create models that clini-
cians can trust. For example, many studies focus on the inter-
pretability of data science tools, the lack of which is one of the
key obstacles to the wide clinical adoption of predictive models.
Ultimately, the clinician is a critical bridge between the patient
and the treatment team. This bridge is even more important as it
allows patient preferences to be integrated into the planning pro-
cess and may in turn change the way the ML/AI model is deployed.
One example would be the development of multiple pareto-
optimal treatment plans that integrate patient preferences into
the final decision-making to select the outcomes most valuable
to the patient. Furthermore, this integration stands to bring about
a shift in the training of medical professionals in radiotherapy; for
example, knowledge about how AI tools work and how to use them
in personalized medicine will replace skills in, for instance, delin-
eation of organs at risk [47,48].The clinician should be involved in data generation and data curation
The constantly increasing power of computers has made col-
lecting and analyzing large amounts of data relatively easy and
allows the building of searchable and expandable databases for
research, modeling, and generation of new hypotheses. Often these
data sets are used only once and then discarded or kept internally
The need for a clinical data science community in oncologyby the originating institution, which limits the power and capabil-
ities of ML/AI for using these data sets. Therefore, the clinician
must play a crucial role in designing and maintaining dedicated
databases for ML model training. Choosing the relevant features
for a clinical problem, considering the defined outcomes, and iden-
tifying possible biases are all still in the domain of clinical exper-
tise [49]. For example, clinical decisions about radical versus
palliative approaches in localized advanced head and neck tumors
are to some extent affected by the clinician’s personal experience
of successful treatments.
The data must be understood by the clinician before any mod-
eling can take place, and clinicians are more willing to use models
if the input features are aligned with evidence-based practice [50].
An example of such a model based on data routinely collected and
updated every hour from electronic records of intensive care unit
patients has been described by Thorsen-Meyer et al. [51]. However,
models should not only use patient characteristics known to be
important, but also uncover previously unknown associations.
Here again, the clinician can help distinguish a truly novel predic-
tive variable from biases, data set artefacts, or confounding factors.
Additionally, clinicians can easily provide feedback in case of a
false prediction and follow up with a misidentified patient, espe-
cially in cases with an unusual trajectory or medical history [50].
To enable searchable and expandable databases for modeling,
research, and generation of new hypotheses, all data sets must
be shared (adhering to the FAIR principles described above) and
accessible for other institutions to use for training, validation, or
additional analysis. In this respect, several approaches may help
clinicians become more engaged in data collection and curation.
The most important is integration of this process into standard
clinical workflows and standard operating procedures. This will
allow clinical data, treatment planning information, diagnostic
imaging, and outcomes to be seamlessly collected as part of clinical
practice. Such integrated data collection will incentivize physicians
to contribute high-quality data on all patients. Even simple synop-
tic endpoint collection can provide a powerful backbone for large
data set generation. When leveraged properly, rapid learning and
automatic data collection will be crucial for clinicians in this era
of fast progress in new therapeutics as well as technology and
information overload. Crucially, simple methods to share data
safely are necessary. If such methods are implemented properly,
clinicians can derive visible benefits from sharing their efforts,
which will convince them to contribute willingly. Examples of this
could include simple quality assurance and second opinions, rapid
outcome estimates, speed up evaluation of new technologies or
automated workflow acceleration. Moreover, there is evidence that
publication where associated data are shared in accordance with
FAIR principles are cited more frequently [52], creating an addi-
tional incentive for the clinicians.
Publication with open FAIR data available for readers should
also be promoted as such by journal editors, meaning safe reposi-
tories have to be provided for authors. Building a culture of data
sharing, not only within research institutions, but also hospitals
and biotechnology companies is the most important challenge
for the future. Policy makers will have an important role to play
in creating a global structured policy of data sharing. A good exam-
ple is the Final Report and Action Plan from the European Commis-
sion’s Expert Group on FAIR data ‘‘Turning FAIR into reality”, which
paves a way to build infrastructure, recognition of obstacles and
benefits and creates incentives for European research institutions
to participate in data sharing. General concept of transparency
and data sharing concerns also pharmaceutical companies, where
process of sharing data obtained in clinical trials is still in it’s
infancy, mostly due to lack of policies of data sharing. A step for-
ward to change this situation has been done by Miller et al who
developed dedicated score -The Good Pharma Scorecard - to mon-50itor of transparency in process of sponsored research and data
sharing process. To have such policy in place is very important
for industry itself due to increasing pressure of external stakehold-
ers including patients and clinicians to speed up gathering knowl-
edge and evidence by transparent collection of data [53]. Another
initiative with potential to facilitate routine clinical data collection
and sharing is the Real World Data (RWD) framework developed
and proposed by the US Food and Drug Administration. The aim
is to collect post-approval data from electronic health records
(EHR) and other clinical data repositories to generate Real World
Evidence (RWE) of risk and benefits of currently approved prod-
ucts. Such approach promotes shared learning and encourages
stakeholders to use RWE in their research, as well as to use com-
mon data models, unified terminology and data encoding for dif-
ferent sources.
Clinicians are crucial not only for defining clinical problems and
relevant outcomes, but also for the dynamic expansion and adap-
tation of databases, accounting for biases and unusual patient tra-
jectories. We cannot forget that all this work should be focused on
individual patient benefits but may also provide population-level
benefits if resources are constrained.The clinician should be involved in all steps of model
development and deployment
An increasing number of clinicians is interested in cooperating
with AI/ML scientists [2]. However, others remain reluctant and
do not yet trust AI models, preventing deployment of these tools
in the clinic [54]. One commonly stated reason for this distrust is
unsatisfactory predictive performance, especially of prognostic
models. However, what level of predictive accuracy is clinically
acceptable is unclear. Moreover, accurate prediction of complex
endpoints like overall survival is very difficult, even for an experi-
enced clinician. A related question is how much better than a
human a model must perform to be considered useful, especially
if the human baseline is low. Many published models perform well
for well-defined, simple outcomes such as prediction of local con-
trol or extracapsular extension in involved head and neck lymph
nodes [55,56].
The most-used metric to measure predictive performance on a
binary classification task is the area under the receiver operating
characteristic curve. To generate predictions for new data, a single
operating point needs to be selected. The standard approach is to
give equal weights to specificity and sensitivity, but in many real
clinical situations the cost of error may vary and may differently
affect patients’ outcomes. For example, a model that incorrectly
suggests a patient will have a very high risk of toxicity may deprive
the patient of the possibility to receive curative therapy. Only by
knowing the holistic clinical picture can one decide how to define
the expected parameters of models, including the desired speci-
ficity and sensitivity of predictions. The role of the clinician in
defining these optimal operating points is crucial. Clinicians should
also be involved in the model review and development to prevent
‘blind alleys’ and other problems.
The accuracy of a model is said to be inversely proportional to
its explainability [57]. The trade-off between explainability and
accuracy is still an unsolved problem, as the best-performing mod-
els based on deep learning are ‘‘black boxes”—synonymous with a
lack of transparency and understanding—and are the least explain-
able. The results of successful attempts to improve the explainabil-
ity of neural networks in health care were published by Yang [58].
However, even an explainable model may not be clinically
applicable/actionable if the output is not additive or meshed into
existing clinical approaches. It is vital that all models grow from
and additively expand to fit existing clinical knowledge. Rediscov-
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can be avoided by incorporating clinical knowledge early in the
problem domain and establishing target areas to enhance [59].
Hence, ideally, models should be organically integrated with prac-
tice to provide continuous feedback, allowing clinicians to monitor
and understand their effects and limitations.
Any model, no matter how accurate and interpretable in the
development stage, needs to be thoroughly validated in a con-
trolled trial before clinicians can trust it.
Validating AI models will require new trial design, especially in
terms of endpoints and evaluation criteria. Nagendran et al found
only two completed and published randomized controlled trials
(RCTs), of AI algorithms in gastroenterology and ophthalmology
[60,61,62], while the FDA has approved more than 16 deep learn-
ing algorithms in ophthalmology, radiology and cardiology. The
most often used endpoint in such studies is the performance of
AI/ML tools on some metric (e.g. receiver operating characteristic)
versus human experts. However, ever if the AI outperforms human
experts, it is not clear whether replacing the clinician’s experience
by an automated algorithm translates into benefit for patients in
real-world use. Additionally, many clinical tasks have no well-
defined ground truth, making an objective, direct comparison diffi-
cult. Endpoints such as performance of clinician supported by an
algorithm, improved workflow efficiency or time and financial sav-
ings could better reflect the real-world impact of clinical AI.
Another challenge in model validation is how to evaluate and
update models under data distribution shift, for example when
the treatment guidelines or patient population change. Policy
changes, such as the regulatory framework for AI/ML Software as
a Medical Device recently proposed by the FDA, can help build clin-
ician trust in AI models by enforce transparency and continuous
performance monitoring as part of the approval process.
Good performance in a retrospective test set is not sufficient;
for example, a model can perform well in data from the institution
where it was developed in but fail when tested on data from a dif-
ferent hospital, despite seemingly identical input data and targets.
This can happen because of covariate shift—a change in the distri-
bution of input data between different institutions, such as differ-
ent CT scanner models and protocols—and because of unobserved
confounders that have real impact on outcomes, like the quality
of the health care system, the provision of supportive care, and
even the approach of individual clinician treating the patient. Con-
tinuously reporting model accuracy at each deployed institution
with individual physicians’ feedback will be critical to maintaining
and monitoring models and will help to ensure that physicians
maintain confidence in the approach.
To fully take advantage of this opportunity, clinician involve-
ment is necessary at every step—from formulating the problem,
through the selection of appropriate input data and prediction tar-
gets, to model validation in a prospective clinical trial.
Data collection, curation and model development will require
both financial and human resources. Recent rapid progress in AI
has led to increased public interest and expectations of many
stakeholders, including patients, regulators and governments.
Resource allocation to AI research and implementation — both on
central level, like EC and local institutional boards — is therefore
expected to increase in the near future.
Moreover, systemic solutions and infrastructure like automatic
data collection, rapid learning systems, standardized format of col-
lection, easy retrieval and seamless integration with the clinical
workflow will reduce the load on clinicians and make the shift
smooth and effective.
To be trustworthy and actionable, the predictions need to be
interpretable, although the balance between interpretability and
accuracy is still a subject of research. Interpretation and prospec-
tive validation, with identification of biases and confounding51factors, preferably in a clinical trial, will increase clinician trust
and allow for deployment of ML tools in the clinic.Statement 5: From AI to a patient-oriented view
Realizing AI’s potential in clinical practice calls for a patient-
centered perspective in the development, design, and implementa-
tion of AI tools. First, AI tools must be oriented towards addressing
clinical questions that matter to patients. Second, the output of AI
tools must be integrated into decision aids that present relevant
clinical information in a format that is clear, understandable, and
actionable [63]. Finally, AI-based model outputs must be explain-
able and be combinable with patient preferences in a shared
decision-making process.AI to enable retrieving patient data
Orienting AI towards the patient perspective involves determin-
ing what is relevant to patients in clinical terms as well as how
they experience their condition. Certain aspects of these data are
routinely collected as patient-reported outcome measures
(PROMs) and stored in patients’ EHRs. It is unclear to what extent
PROMs are analyzed and used [64], particularly due to doctors’ lack
of time, resources, and expertise [65]. This presents an opportunity
for AI/ML techniques to harness and analyze EHR data and PROMs
to identify relationships between treatments and patient-relevant
outcomes [66].
Aside from patient data stored in hospital records, increasing
amounts of data are also generated externally, as more patients,
through use of the internet, are taking an active role in managing
their health decisions. Consequently, the role of patient organiza-
tions is also shifting from providing information to building plat-
forms and online communities in which patients can share
experiences and knowledge that go beyond the data captured in
PROMs. For instance, the patient organization PatientsLikeMe, an
online community that connects over 650,000 patients across
nearly 3000 health conditions, is based on the principle of seeing
the patient as a person rather than as a disease, and accordingly
collects data on patients’ definitions of health and outcomes.
PatientsLikeMe is actively involved in AI initiatives to generate
insights from this vast and rich data source [67]. Initiatives such
as these can help target AI tools to clinically relevant questions.Clinical decision aids for doctors and patients
AI tools must be built into decision aids that support shared
deliberation and decision-making processes between patients
and doctors. Decision aids provide a means to inform patients
about their conditions, reflect on their own values, and weigh their
treatment options in the context of their preferences. Poor design
is one of the main factors that hinders decision aid uptake [68].
Implementation of AI-enhanced decision aids is more likely to suc-
ceed when development follows a user-centered design process
that takes into account end-users’ contexts, needs, goals, and
decision-making [69]. We have previously emphasized the impor-
tance of including doctors in the development process, as well as
the patient focus in determining relevant clinical questions. Once
developed, it is critical that decision aids be embedded into the
clinical workflow, for instance through integration into the hospi-
tal’s EHR system, to minimize the amount of time and manual
work required in entering a patient’s data [70]. In addition, inte-
grating the decision aid into the clinical consultation itself can pave
the way for data-driven shared decision-making in which AI-based
recommendations are discussed in the context of the doctor’s clin-
ical knowledge/experience and the patient’s preferences.
Fig. 3. Overview of the structure of the new data science community in radiation oncology. In line with the presented milestones, five major working groups are identified:
FAIR principles group (M1); standardization group (M 2); AI applications and big data collaborative infrastructures group (M3); clinical research and definition of unmet
clinical needs group (M4); and patient-centered decision aids and shared decision-making group (M5). The role of each group is to coordinate with similar existing task forces
and working groups from European and American societies active in radiation oncology.
The need for a clinical data science community in oncologyBringing AI into the consultation
Traditional shared decision-making consists of a two-way infor-
mation exchange between doctors and patients; doctors share their
clinical expertise on the treatment options and their benefits and
risks, and patients share their values and preferences [71]. When
both sides understand each others’ perspectives, they can deliberate
on the available options from a common ground and make a choice
that is rooted in the best clinical evidence as well as the patient’s
individual circumstances. The introductionof AI-baseddecision aids
represents a third angle from which treatment information can be
personalized according to the patient’s individual characteristics
[72]. The ‘‘blackbox” nature of certainAI toolsmaymake it challeng-
ing for the doctor to articulate the reasoning behind a given diagno-
sis or treatment recommendation [73], so the explainability of theAI
tool is a crucial factor in ensuring that decision-making does not
shift back towards paternalism [74]. This includes interpreting AI
model outputs, such as risk estimates or prognoses, and communi-
cating them in a way that is understandable to patients [75].
Moreover, little is known about the patient perspective on
receiving AI-supported care. Preliminary findings from skin cancer
screening suggest that patients are open to the potential of AI in
improving care quality as long as it functions as decision support
rather than decision replacement [76] and the doctor-patient dyad
is maintained [58]. More research is needed to understand the shift
in roles and responsibilities that accompanies AI implementation
and how to use AI models to empower patients. In particular, the
perspectives of social scientists and anthropologists are needed
to bring AI into alignment with human decision-making [77].
Discussion
In this paper, we identified the barriers that are currently limit-
ing the adoption of big data analytics in the clinic toward the
development of a learning health care system. The main barrier
is the ability to handle the large amount of data and metadata pro-52duced in the clinic as result of daily clinical and research activities.
As we discussed, this big data involves different stakeholders and
users and presents significant interoperability issues. We therefore
identified the need to analyze the major sources of multisource
data and metadata and the limits on their interoperability (mile-
stones M1 and M2).
We next discussed how, when it becomes capable of fully con-
necting these sparse multisource data, AI will provide powerful
analytics to develop data-driven clinical decision aids (milestone
M3). However, because of the variety of data types and stakehold-
ers involved, multiple professionals need to be involved and coor-
dinated. For this reason, we presented the need to define a clinical
data science community in radiation oncology, to act as harmo-
nizer of the different professional figures with a common vision
sustained by a code of conduct and working statements and with
a strong orientation toward patient-centered care (milestone
M5). This community will not be an independent actor, but will
build upon already existing communities, efforts, and working
groups. Clinicians will have a prominent leading role both in deter-
mining the requirements of the technical developments and in
continuously interfacing with the more technical professionals.
This is meant to guarantee that technical developments are in line
with unmet clinical needs. We envision this community to be fully
embedded within the major global radiation oncology societies,
such as ESTRO, ASTRO, CARO, AAPM, EFOMP, RANZCR and FARO
and to include patient societies such as CRC and PatientsLikeMe.
Our future activities will be to engage with the above-
mentioned societies to define working groups, as briefly depicted
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